Compare IDEXX Laboratories, Inc. (IDXX) vs Progressive Corp (PGR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Progressive Corp — how do they compare? IDEXX Laboratories, Inc. trades at $573.33 (market cap $46.22B), while Progressive Corp trades at $207.81 (market cap $123.45B). The key difference: Progressive Corp is far larger — about 2.7× IDEXX Laboratories, Inc.'s market cap, and Progressive Corp pays a 6.55% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | PGR | |
|---|---|---|
Market Cap | $46.22B | $123.45B |
Sector | Health | Financials |
52-Week High | $766.68 | $252.68 |
52-Week Low | $526.44 | $190.40 |
Enterprise Value | $47.12B | $131.66B |
Dividend Yield | — | 6.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
PGR trades at $208.28, down 2.65% on the day, with a bearish technical signal. The stock shows strong fundamentals with a P/E of 10.65, net income margin of 12.85%, and robust revenue growth from $49.6B in 2022 to $87.6B in 2025. Recent Q2 2026 earnings beat expectations at $4.85 EPS, though Q1 2026 missed. Analyst consensus is a buy with a $231.20 price target, but technical indicators suggest near-term caution.
Outlook remains positive due to solid profitability and growth, but risks include competitive pressures and potential margin compression. The stock offers value at current levels with upside to analyst targets, though investors should monitor execution on growth initiatives and industry dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →
